Walleye Capital LLC Takes Position in Tyra Biosciences, Inc. $TYRA

Walleye Capital LLC bought a new stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 18,715 shares of the company’s stock, valued at approximately $717,000.

A number of other hedge funds have also recently bought and sold shares of TYRA. Commodore Capital LP lifted its holdings in Tyra Biosciences by 226.3% in the 2nd quarter. Commodore Capital LP now owns 3,100,000 shares of the company’s stock valued at $29,667,000 after acquiring an additional 2,150,000 shares during the last quarter. Janus Henderson Group PLC grew its stake in shares of Tyra Biosciences by 2.1% in the 4th quarter. Janus Henderson Group PLC now owns 2,935,442 shares of the company’s stock worth $77,085,000 after purchasing an additional 60,638 shares during the last quarter. Farallon Capital Management LLC raised its holdings in shares of Tyra Biosciences by 80.7% in the 4th quarter. Farallon Capital Management LLC now owns 2,066,818 shares of the company’s stock worth $54,337,000 after purchasing an additional 923,000 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Tyra Biosciences by 8.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,520,185 shares of the company’s stock worth $21,267,000 after purchasing an additional 118,492 shares in the last quarter. Finally, 5AM Venture Management LLC lifted its stake in Tyra Biosciences by 9.6% during the fourth quarter. 5AM Venture Management LLC now owns 1,029,298 shares of the company’s stock valued at $27,060,000 after purchasing an additional 90,000 shares during the last quarter. 84.14% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $45.00 price target on shares of Tyra Biosciences in a research report on Thursday, May 14th. Bank of America raised their price objective on Tyra Biosciences from $37.00 to $42.00 and gave the stock a “buy” rating in a research note on Wednesday, June 10th. Canaccord Genuity Group initiated coverage on Tyra Biosciences in a report on Monday, April 6th. They issued a “buy” rating and a $50.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Friday, July 17th. Finally, Guggenheim initiated coverage on Tyra Biosciences in a report on Tuesday, April 14th. They set a “buy” rating and a $54.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $47.00.

Tyra Biosciences Price Performance

TYRA stock opened at $30.63 on Friday. Tyra Biosciences, Inc. has a 52-week low of $9.96 and a 52-week high of $40.65. The company’s 50 day simple moving average is $30.68 and its 200-day simple moving average is $32.56. The firm has a market capitalization of $1.82 billion, a P/E ratio of -14.05 and a beta of 0.76.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.04). Sell-side analysts predict that Tyra Biosciences, Inc. will post -2.68 EPS for the current fiscal year.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.